Erta Kalanxhi - Search Results

Year	Number of Results
2007	1
2009	1
2011	2
2012	3
2014	2
2016	3
2017	1
2018	1
2019	1
2020	2
2021	0

1

Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer.

Kalanxhi E, Meltzer S, Ree AH. Kalanxhi E, et al. Cancers (Basel). 2020 Aug 6;12(8):2193. doi: 10.3390/cancers12082193. Cancers (Basel). 2020. PMID: 32781554 Free PMC article. Review.

2

Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Meltzer S, et al. Among authors: kalanxhi e. Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27. Transl Oncol. 2019. PMID: 31146167 Free PMC article.

3

Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044].

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Meltzer S, et al. Among authors: kalanxhi e. Transl Oncol. 2020 Jan;13(1):122-124. doi: 10.1016/j.tranon.2019.09.005. Transl Oncol. 2020. PMID: 31843135 Free PMC article. No abstract available.

4

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH. Kalanxhi E, et al. Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26. Br J Cancer. 2018. PMID: 29695770 Free PMC article.

5

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Ree AH, et al. Among authors: kalanxhi e. Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Int J Mol Sci. 2014. PMID: 25501337 Free PMC article. Review.

6

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH. Kalanxhi E, et al. BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x. BMC Cancer. 2016. PMID: 27461255 Free PMC article. Clinical Trial.

7

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Meltzer S, et al. Among authors: kalanxhi e. Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995. Oncotarget. 2016. PMID: 27145458 Free PMC article.

8

The role of serotonin and p53 status in the radiation-induced bystander effect.

Kalanxhi E, Dahle J. Kalanxhi E, et al. Int J Radiat Biol. 2012 Oct;88(10):773-6. doi: 10.3109/09553002.2012.711919. Epub 2012 Aug 2. Int J Radiat Biol. 2012. PMID: 22803606

9

Transcriptional responses in irradiated and bystander fibroblasts after low dose α-particle radiation.

Kalanxhi E, Dahle J. Kalanxhi E, et al. Int J Radiat Biol. 2012 Oct;88(10):713-9. doi: 10.3109/09553002.2012.704657. Epub 2012 Jul 18. Int J Radiat Biol. 2012. PMID: 22765265

10

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH. Kalanxhi E, et al. Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28. Cancer Res Treat. 2017. PMID: 27488871 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results